Top

Supportive Care in Cancer

Published in:

Open Access 01-12-2012 | Original Article

Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy

Authors: Vito Lorusso, Marianna Giampaglia, Luciana Petrucelli, Valeria Saracino, Tania Perrone, Antonio Gnoni

Published in: Supportive Care in Cancer | Issue 12/2012

Abstract

Introduction

The goal of pharmacological prophylaxis of chemotherapy-induced nausea and vomiting (CINV) should be the elimination of both nausea and vomiting symptoms during all planned chemotherapy cycles. The aim of this study was to assess the efficacy of a single dose of palonosetron and dexamethasone to prevent CINV and to guarantee an adequate food intake (FI) in patients receiving several cycles of multiple day-based chemotherapy (MD-CT).

Methods

Patients with advanced cancer but without a compromised nutritional status (bone mass index ≥ 18.5) were treated with 0.25 mg palonosetron plus 20 mg dexamethasone before MD-CT. The MD-CT regimen was either epirubicin plus ifosfamide or paclitaxel plus cisplatin and ifosfamide. Nausea, vomiting, and FI were monitored in a 7-day diary. Complete response (CR: no vomiting and no rescue therapy) was the primary endpoint, while complete control (CC: CR and no more than mild nausea) and the evaluation of FI were secondary endpoints. The endpoints were evaluated during the overall timescale (0–168 h) of the chemotherapy regimen.

Results

Fifty patients were enrolled, 80% of whom achieved CR and 78% achieved CC. During the six chemotherapy cycles, CR and CC ranged from 76% to 88% and from 62% to 88%, respectively. Moreover, patients with CR had a significantly (p < 0.0001) higher weekly food intake compared with patients not achieving CR.

Conclusions

This trial was the first to assess the efficacy of palonosetron and dexamethasone for the prevention of both nausea and vomiting in patients receiving multiple cycles of MD-CT. In this trial, the ability of patients to intake an adequate amount of food each week was correlated with nausea, thus providing clinicians with an objective parameter for the measurement of the effects of nausea. A single dose of palonosetron and dexamethasone was able to prevent CINV in most patients receiving 3 days of chemotherapy during all planned chemotherapy cycles.

Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494PubMedCrossRef

De Wit R, Van Den Berg H, Burghouts J et al (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Brit J Cancer 77(9):1487–1491PubMedCrossRef

Sigsgaard T, Herrstedt J, Handberg J et al (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19(7):2091–2097PubMed

De Wit R, Herrstedt J, Rapoport B et al (2003) Addition of the oral NK 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105–4111PubMedCrossRef

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E (2008) Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 94:447–452PubMed

Navari RM (2007) Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Cancer Netw 5(1):51–59

Saito M, Tsukuda M (2010) Review of palonosetron: emerging data distinguishing it as a novel 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 11(6):1003–1014PubMedCrossRef

Antiemesis (2011) NCCN clinical practice guidelines in oncology. V.3. 2011. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf [last accessed 4 May 2011]

Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232–v243PubMedCrossRef

10.

Eisenberg P, Figuero-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist. Results of a phase III, single dose trial versus dolasetron. Cancer 98(11):2473–2482PubMedCrossRef

11.

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577PubMedCrossRef

12.

Rubenstein EB, Gralla RJ, Eisenberg P (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Combined results of two phase III trials. Proc Am Soc Clin Oncol 22:729–A2932

13.

Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449PubMedCrossRef

14.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124PubMedCrossRef

15.

Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822–2830PubMedCrossRef

16.

Khojasteh A, Khojasteh A, Thornburg BG et al (2009) Casopitant: a new warrior in the antiemetic crusade. Expert Opin Pharmacother 10(8):1367–1376PubMedCrossRef

17.

Lorusso V, Spedicato A, Petrucelli L et al (2009) Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer 17(12):1469–1473PubMedCrossRef

18.

Cartmell AD, Ferguson S, Yanagihara R et al (2003) Protection against chemotherapy-induced nausea and vomiting (CINV) is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron (PALO), a potent 5-HT3 receptor antagonist (RA). Proc Am Soc Clin Oncol 22: 2003 (abstr 3041)

19.

Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S et al (1999) Perception of chemotherapy side effects cancer versus non cancer patients. Cancer Pract 7:59–65PubMedCrossRef

20.

Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:10CrossRef

21.

Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300PubMedCrossRef

22.

Rozzi A, Nardoni CA, Corona M et al (2009) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19:697–701CrossRef

23.

Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F et al (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 17(2):205–209PubMedCrossRef

24.

Aapro M, Fabi A, Nolè F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol May 21(5):1083–1088, Epub 2010 Jan 15CrossRef

25.

Celio L, Frustaci S, Denaro A, et al (2010 June 25) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225

26.

Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015

27.

Rubenstein EB (1994) Costs and benefits of outpatient therapy. Support Care Cancer 2(5):307–311PubMedCrossRef

28.

Stoltz R, Cyong JC, Shah A et al (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44:520–531PubMedCrossRef

29.

Wong EH, Clark R, Leung E et al (1995) The interaction of RS 25259–197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114(4):851–859PubMedCrossRef

30.

Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478PubMedCrossRef

31.

Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2–3):193–199PubMedCrossRef

Title: Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
Authors: Vito Lorusso
Marianna Giampaglia
Luciana Petrucelli
Valeria Saracino
Tania Perrone
Antonio Gnoni
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 12/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1469-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2012

Lung cancer and rehabilitation—what are the barriers? Results of a questionnaire survey and the development of regional lung cancer rehabilitation standards and guidelines

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

A randomized controlled trial comparing two types of pneumatic compression for breast cancer-related lymphedema treatment in the home

Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan

Acceptability and feasibility of family use of The Cellie Cancer Coping Kit

Reply to Letter to the Editor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer